Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kyntra Bio (KYNB) Operating Leases (2019 - 2024)

Historic Operating Leases for Kyntra Bio (KYNB) over the last 6 years, with Q3 2024 value amounting to $2.0 million.

  • Kyntra Bio's Operating Leases fell 9755.8% to $2.0 million in Q3 2024 from the same period last year, while for Sep 2024 it was $2.0 million, marking a year-over-year decrease of 9755.8%. This contributed to the annual value of $65.0 million for FY2023, which is 1829.31% down from last year.
  • Kyntra Bio's Operating Leases amounted to $2.0 million in Q3 2024, which was down 9755.8% from $73.9 million recorded in Q2 2024.
  • In the past 5 years, Kyntra Bio's Operating Leases ranged from a high of $94.2 million in Q2 2021 and a low of $472000.0 during Q3 2020
  • Its 5-year average for Operating Leases is $57.6 million, with a median of $79.6 million in 2022.
  • In the last 5 years, Kyntra Bio's Operating Leases skyrocketed by 1928093.22% in 2021 and then tumbled by 9755.8% in 2024.
  • Kyntra Bio's Operating Leases (Quarter) stood at $853000.0 in 2020, then skyrocketed by 10307.5% to $88.8 million in 2021, then decreased by 10.34% to $79.6 million in 2022, then decreased by 18.29% to $65.0 million in 2023, then plummeted by 96.92% to $2.0 million in 2024.
  • Its last three reported values are $2.0 million in Q3 2024, $73.9 million for Q2 2024, and $77.7 million during Q1 2024.